Toripalimab and radiation for breast cancer not responding to chemo
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining the immunotherapy drug toripalimab with targeted radiation can help patients with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. It aims to find a new treatment option for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer that has spread to nearby lymph nodes but not to distant organs.
- Your cancer is HER2-negative (a type that does not make too much of the HER2 protein).
- After two cycles of chemotherapy before surgery, your tumor stayed the same size (did not shrink).
- You are at least 18 years old.
- You have at least one tumor that can be measured on scans.
- You are willing to provide a small sample of your tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.